Diaceutics (LON:DXRX) Stock Price Up 0.7% – What’s Next?

Diaceutics PLC (LON:DXRX)’s share price shot up 0.7% during mid-day trading on Thursday . The stock traded as high as GBX 146 and last traded at GBX 146. Approximately 67,335 shares changed hands during trading, a decline of 66% from the average daily volume of 195,402 shares. The stock had previously closed at GBX 145.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group upped their price target on Diaceutics from GBX 215 to GBX 216 and gave the company a “buy” rating in a research note on Thursday, June 4th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of GBX 205.33.

Diaceutics Stock Up 0.7%

The company has a market cap of £123.56 million, a price-to-earnings ratio of 1,327.27 and a beta of 0.89. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85. The firm’s fifty day moving average price is GBX 157.60 and its 200-day moving average price is GBX 152.50.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, May 26th. The company reported GBX 11 EPS for the quarter. The business had revenue of GBX 3,844 million for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. Sell-side analysts predict that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.